New drug VIS171 tested in humans for first time – could it tame autoimmune disease?

NCT ID NCT05418101

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VIS171
What this could lead to: If this early study shows VIS171 is safe, it could pave the way for a new treatment option for autoimmune diseases.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (61 people) and may fail to show benefit or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Ambulatory for Specialized Medical Help - skin and venereal diseases

Sofia, 1407, Bulgaria
Clinical republican Hospital

Chisinau, MD 2025, Moldova
Comac Medical Ltd

Sofia, 1612, Bulgaria
Diagnostic and Consultative Center Convex EOOD

Sofia, 1680, Bulgaria
MBAL Sveta Sofia

Sofia, 1618, Bulgaria
New Zealand Clinical Research

Christchurch, 8011, New Zealand
Radboud University Medical Center

Gelderland, 6525, Netherlands
UMHAT

Plovdiv, 4002, Bulgaria
Universitaetsklinikum Bonn AöR

Bonn, 53127, Germany
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz

Rheinland-Pfalz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.